药物诱发非酒精性脂肪性肝病患者肝损伤的机制  

Mechanism of drug-induced liver injury in patients with non-alcoholic fatty liver disease

作　　者：王慧[1] 王炳元[1] 

机构地区：[1]中国医科大学附属第一医院消化内科,沈阳110001

出　　处：《传染病信息》2013年第5期266-267,共2页Infectious Disease Information

基　　金：辽宁省科技厅科技攻关项目(2011225015)

摘　　要：肝脏通过代谢、转运和清除异物等功能在降低药物毒性方面起着至关重要的作用。药物性肝损伤(drug-induced liver injury,DILI)是西方国家急性肝衰竭的主要病因,由于久坐的生活方式和摄入热量过度,我国还面临着肥胖和非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)的困扰。脂肪肝可增大各种疾病(如糖尿病、心血管疾病和不孕不育症等)的风险,是威胁公众健康的又一主要问题。为了治疗相关疾病,NAFLD患者平均使用的药量远高于非NAFLD患者,增大了患DILI的风险。希望临床医生重视该特殊人群用药的安全性。Liver plays a crucial role in eliminating the toxicity of drugs due to its function in the metabolism, transport, and clearance of foreign substances. In Western countries, drug-induced liver injury （DILI） is the major cause of acute liver failure. Moreover, we are also facing the problems of obesity and non-alcoholic fatty liver disease （NAFLD） in China, due to the sedentary lifestyle and calorie overeonsumption. NAFLD poses a major public health problem since it primarily enhances the risk of various ill- nesses, such as diabetes, cardiovascular disease and infertility, etc. For the treatment of related diseases, NAFLD patients are con- suming more drugs than non-NAFLD individuals, which increases the risk of DiLL Therefore, it is hoped that clinicians should pay attention to safety issues of drug use in NAFLD patients.

关 键 词：脂肪肝 药物性肝损伤 病理过程 

分 类 号：R575.5[医药卫生—消化系统]